Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects

Diabetes Research and Clinical Practice

Volumn 56, Issue 2, 2002, Pages 101-106

  DeLeon, Mary Jeanne ^a   Chandurkar, Vikram ^a   Albert, Stewart G ^a   Mooradian, Arshag D ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Acarbose; Aging; Alpha glucosidase inhibitors; Glucagon like peptide 1; Type 2 diabetes

Indexed keywords

ACARBOSE; ALPHA GLUCOSIDASE INHIBITOR; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; INSULIN; TRIACYLGLYCEROL;

AGE; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG MECHANISM; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; INSULIN BLOOD LEVEL; MALE; MEAL; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; PROTEIN BLOOD LEVEL; TIME; TRIACYLGLYCEROL BLOOD LEVEL;

ACARBOSE; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; EATING; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PEPTIDE FRAGMENTS; POSTPRANDIAL PERIOD; PROTEIN PRECURSORS; TRIGLYCERIDES;

EID: 0036124589     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8227(01)00359-X     Document Type: Article

References (17)

1. Glucagon-like peptide-1 (GLP-1) as a new therapeutic approach for type 2 diabetes
2. Glucagon-like peptide-1 (GLP-1) [7-36 amide] secretion in response to luminal sucrose from the upper and lower gut. A study using α-glucosidase inhibition (acarbose)
3. Prolonged and enhanced secretion of glucagons-like peptide 1 (7-36 amide) after oral sucrose due to alpha-glucosidase inhibition (acarbose) in type 2 diabetic patients
4. Differences in glucagon-like peptide-1 and GIP responses following sucrose ingestion
5. Voglibose (AO-128) is an efficient α-glucosidase inhibitor and mobilizes endogenous GLP-1 reserve
6. Effects of age on concentrations of plasma cholecystokinin, glucagons-like peptide-1 and peptide YY and their relation to appetite and pyloric motility
7. The aging entero-insular axis
8. Glucagon-like peptide (GLP)-1 and leptin concentrations in obese patients with type 2 diabetes mellitus
9. Reduced postprandial concentrations of intact biologically active glucagons-like peptide 1 in type 2 diabetic patients
10. Gut incretin hormones in identical twins discordant for non-insulin-dependent diabetes mellitus (NIDDM)-evidence for deceased glucagons-like peptide 1 secretion during oral glucose ingestion in NIDDM twins
11. Potential of α-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucagons tolerance
12. Drug therapy of non-insulin dependent diabetes in the elderly
13. Report of the expert committee on the diagnosis and classification of diabetes mellitus
14. Dose-response profile of acarbose in older subjects with type 2 diabetes
15. Advantages of alpha-glucosidase inhibition as monotherapy in elderly type 2 diabetic patients
16. The postprandial state and the risk of atherosclerosis
17. Preserved incretin activity of glucagons-like peptide 1 (7-36 amide) but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus